Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BDI Pharma, a wholesaler of biopharmaceutical products, has posted strong growth in sales of Wyeth’s XYNTHA Antihemophilic Factor (Recombinant) for the first quarter of 2009. Sales in the US exceeded BDI’s projections by 22% in Q1. XYNTHA is a Plasma-Free and Albumin-Free recombinant factor VIII product.
Subscribe to our email newsletter
William Shirey, Executive VP of BDI, said: “The fact that our company’s sales for XYNTHA have tracked twenty-two percent (22%) ahead of the results forecasted for the first fiscal quarter and continue to pace at an even greater rate thus far for Q2, reflects BDI’s ability to assist its trade partners with the introduction of new products, the development of brand identity and the generation of vital market share.”
FDA approved XYNTHA controls and prevents bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia), and also used for surgical prophylaxis in patients with hemophilia A.